Sclerosis News and Research

RSS

CD4 T cells orchestrate inflammatory attack on the artery wall

Most people probably know that heart disease remains the nation's No. 1 killer. But what many may be surprised to learn is that cholesterol has a major accomplice in causing dangerous arterial plaque buildup that can trigger a heart attack. The culprit? Inflammatory cells produced by the immune system.

15 Aug 2012

ALS risk markedly lower among alcohol consumers

A population-based case-control study of the rare but devastating neurological disease amyotrophic lateral sclerosis (ALS) has shown that the risk of such disease is increased among smokers, as has been shown previously. However, surprisingly, the risk of ALS was found to be markedly lower among consumers of alcohol than among abstainers.

13 Aug 2012

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Acorda Therapeutics, Inc. today announced top line results from a post-marketing commitment study evaluating a 5mg dose of dalfampridine-ER to improve walking in people with multiple sclerosis. The study failed to confirm efficacy of the 5mg dose.

13 Aug 2012

Active Biotech, Teva to commence third Phase III study of laquinimod for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).

9 Aug 2012

FDA approves Codman’s MEDSTREAM Programmable Infusion System

Codman & Shurtleff, Inc. (Codman), the global neurological device company, has received U.S. Food and Drug Administration (FDA) approval through a PMA supplement for its MEDSTREAM Programmable Infusion System, an implantable infusion pump and catheter system used in the treatment of spasticity, a movement disorder often caused by stroke, cerebral palsy, multiple sclerosis or spinal cord injury.

9 Aug 2012

Cannabis-based medications prove effective in relieving pain

Cannabis-based medications have been proved to relieve pain. This is the conclusion drawn by Franjo Grotenhermen and Kirsten Müller-Vahl in issue 29-30 of Deutsches Ärzteblatt International.

7 Aug 2012

Study investigates role of inflammation in ALS mouse model

Amyotrophic lateral sclerosis (ALS) is a progressive disease wherein the cells of the central nervous system (CNS) involved in movement and coordination are destroyed. Although the mechanism of ALS is not completely understood, inflammation is believed to play a role in the disease process. A recent study by Howard Weiner and colleagues at Harvard Medical School and Tufts School of Medicine investigated the role of inflammation in a mouse model of ALS.

7 Aug 2012

Changes in monocytes are biomarker for amyotrophic lateral sclerosis

Researchers from Brigham and Women's Hospital (BWH) are the first to discover that changes in monocytes (a type of white blood cell) are a biomarker for amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease. This finding also brings the medical community a step closer toward a new treatment for the debilitating neurological disease that affects approximately 30,000 Americans.

7 Aug 2012

UI Hospital implants NeuRx Diaphragm Pacing System in a patient with ALS

The University of Illinois Hospital & Health Sciences System is one of only a dozen hospitals nationwide to implant the NeuRx Diaphragm Pacing System in a patient with amyotrophic lateral sclerosis (ALS).

3 Aug 2012

Anacardic acid can rescue some ALS phenotypes in vitro

A research group at the Center for iPS Cell Research and Application (CiRA) at Japan's Kyoto University has successfully recapitulated amyotrophic lateral sclerosis (ALS)-associated abnormalities in motor neurons differentiated from induced pluripotent stem cells (iPSCs) obtained from patients with familial ALS, a late-onset, fatal disorder which is also known for Lou Gehrig's disease. In a drug screening assay using the disease model, the team further found that the chemical compound anacardic acid can rescue some ALS phenotypes in vitro.

3 Aug 2012

Weill Cornell Medical College receives NCATS grant to fund Clinical and Translational Science Center

Weill Cornell Medical College has received $49.6 million from the National Center for Advancing Translational Sciences (NCATS), of the National Institutes of Health (NIH), to fund its Clinical and Translational Science Center (CTSC).

3 Aug 2012

Scientists link some cases of Essential Tremor to specific genetic problem

Researchers at the University of Montreal and its affiliated CHU Sainte-Justine and CHUM hospitals have linked some cases of Essential Tremor (ET) to a specific genetic problem. ET is the most common movement disorder, becoming increasingly frequent with increasing age, which is characterized by an involuntary shaking movement (tremor) that occurs with motion, particularly when doing precise fine movement.

3 Aug 2012

B-cell substances may play a role in MS progression

Wayne State University School of Medicine researchers, working with colleagues in Canada, have found that one or more substances produced by a type of immune cell in people with multiple sclerosis (MS) may play a role in the disease's progression. The finding could lead to new targeted therapies for MS treatment.

2 Aug 2012

Advanced understanding of neurodegenerative diseases achieved by Trophos

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to the EC.

31 Jul 2012

Cedars-Sinai to develop stem cell treatments for patients with ALS

Cedars-Sinai Regenerative Medicine Institute today was awarded a $17.8 million grant from the California Institute for Regenerative Medicine to develop stem cell treatments for patients with ALS, also known as Lou Gehrig's Disease, a progressive, fatal and currently incurable neurodegenerative disease.

30 Jul 2012

New device makes it possible to draw and write using just eye movements

A novel device that makes it possible to draw and write using just eye movements has been developed by a CNRS researcher at the Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière (CNRS/UPMC/Inserm).

28 Jul 2012

Long-term interferon beta benefits unclear in MS

A large “real-world” study fails to show reduced disability progression in patients with relapsing-remitting multiple sclerosis given interferon beta.

26 Jul 2012

AHAF announces glaucoma and macular degeneration research grants

The American Health Assistance Foundation, a nonprofit organization with a history of funding breakthrough research on age-related vision diseases, announced today that it has awarded 21 new grants totaling $2.1 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible blindness in the world.

26 Jul 2012

Elan second quarter total revenue increases 6% to $288.0 million

Elan Corporation, plc today reported its second quarter and first half 2012 financial results.

25 Jul 2012

PAMAM G-3 actually prevents activation of the process that leads to thrombosis

A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges -- stopping the formation of blood clots without triggering equally threatening bleeding.

24 Jul 2012